Last reviewed · How we verify
Isotonic 0.3% Sodium Hyaluronate
Sodium hyaluronate is a viscoelastic substance that lubricates and protects ocular surfaces by mimicking natural tear film components.
Sodium hyaluronate is a viscoelastic substance that lubricates and protects ocular surfaces by mimicking natural tear film components. Used for Dry eye syndrome / Keratoconjunctivitis sicca, Ocular surface protection and lubrication.
At a glance
| Generic name | Isotonic 0.3% Sodium Hyaluronate |
|---|---|
| Also known as | Arm B |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Sodium hyaluronate is a high-molecular-weight polysaccharide that acts as a humectant and lubricant on the ocular surface. It binds water and forms a protective layer over the cornea and conjunctiva, reducing friction and promoting epithelial healing. This isotonic 0.3% formulation is designed for topical ophthalmic use to treat dry eye and related surface disorders.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Ocular surface protection and lubrication
Common side effects
- Transient blurred vision
- Eye irritation or discomfort
- Conjunctival hyperemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isotonic 0.3% Sodium Hyaluronate CI brief — competitive landscape report
- Isotonic 0.3% Sodium Hyaluronate updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI